Pharmaceuticals News and Research

RSS

Pharmaceutical Institute launches Employers and Retail Pharmacy e-courses

Pharmaceutical Institute, a leading provider of specialized training solutions for the pharmaceutical and biotech industry, today announced the launch of two new e-courses, titled Employers and Retail Pharmacy.

18 Feb 2010

Quintiles launches QTEA solution to speed patient recruitment

Quintiles today launched innovative, web-based technology to enable world-class marketing for clinical trial enrolment at an individual site-level. Named Quintiles Trial Enrolment Accelerator (QTEA), this new solution will speed patient recruitment by helping customers better manage the quality, consistency and effectiveness of messaging and media outreach.

18 Feb 2010

Roche Molecular Systems, Merck Sharp & Dohme announce cancer therapeutics collaboration

Roche Molecular Systems, Inc. announced today a research collaboration with Merck Sharp & Dohme Corp. (a subsidiary of Merck & Co., Inc.) providing Merck access to Roche's developmental microarray-based AmpliChip p53 Test, which is designed to detect mutations in the tumor suppressor gene p53. By identifying cancers that harbor a dysfunctional p53 gene, the companies aim to achieve better treatment outcomes in cancer patients by determining which patients are most likely to respond to certain investigational therapeutic candidates.

18 Feb 2010

Javelin Pharmaceuticals’ Dyloject NDA receives FDA PDUFA date

Javelin Pharmaceuticals, Inc., a leading developer and marketer of specialty pharmaceutical products for pain management, today announced that its New Drug Application (NDA) submitted on December 2, 2009 to the US Food and Drug Administration (FDA) for its investigational product candidate, Dyloject™ (diclofenac sodium) Injection, has received an FDA PDUFA date of October 3, 2010. This NDA review is in support of US marketing approval and registration of Dyloject for the management of acute moderate-to-severe pain in adults.

18 Feb 2010

Genzyme announces fourth-quarter and full-year 2009 financial results

Genzyme Corp., a diversified, global biotechnology company, today announced fourth-quarter and full year 2009 financial results and provided 2010 guidance that reflects growth across its businesses and a focus on strengthening core areas of the company.

18 Feb 2010

Codexis announces two separate collaborations in pharmaceutical manufacturing

Codexis, Inc. today announced two separate collaborations in pharmaceutical manufacturing with Dishman Pharmaceuticals and Chemicals and AMPAC Fine Chemicals LLC, a subsidiary of American Pacific Corporation. These agreements expand the application of Codexis technology to a broadened pipeline of branded innovator pharmaceutical products.

17 Feb 2010

Athersys completes enrollment in phase I MultiStem allogeneic stem cell therapy clinical trial

Athersys, Inc. and Angiotech Pharmaceuticals, Inc. announced that Athersys has completed patient enrollment for its phase I clinical trial of MultiStem(R), its allogeneic stem cell therapy product, administered to individuals following acute myocardial infarction (AMI), more commonly referred to as a heart attack. Top line results of the trial are expected to be announced midyear, upon completion of the four-month patient follow-up visits and analysis of results.

17 Feb 2010

Tioga Pharmaceuticals to utilize $18M equity funding for Phase 3 clinical trial of asimadoline

Tioga Pharmaceuticals, Inc. today announced the closing of an $18 million equity financing. Current investors Forward Ventures, New Leaf Venture Partners and BB Biotech Ventures were joined by new investor Genesys Capital Partners.

17 Feb 2010

Pharmatek Laboratories meets DEA requirements for developing and manufacturing controlled substances

Pharmatek Laboratories, Inc., a premier contract development and manufacturing organization supporting the pharmaceutical industry, announced that it has successfully met Drug Enforcement Agency (DEA) requirements to be registered for the development and manufacture of Schedule IV and V controlled substances.

17 Feb 2010

Dyax announces fourth-quarter and full-year 2009 financial results

Dyax Corp. today announced financial results for the fourth quarter and year ended December 31, 2009. Dyax will host a webcast and conference call at 10 a.m. (ET) this morning to review the financial results and corporate progress for the quarter.

17 Feb 2010

FDA approved cannabis medicines needed for veterans to relieve symptoms of PTSD

Cannabis Science Inc., an emerging pharmaceutical cannabis company, is reviewing interim results of its survey from over 1400 people, US military veterans and others who responded to our PTSD survey. The survey is still available for a limited time online on the www.cannabisscience.com website for all those who still wish to participate.

17 Feb 2010

Derma Sciences announces pricing of public offering of 972,000 shares of its common stock

Derma Sciences, Inc., a specialty medical device and pharmaceutical company focused on advanced wound care, today announced the pricing of a public offering of 972,000 shares of DSCI common stock and 324,000 warrants to purchase shares of common stock at a price of $5.50.

17 Feb 2010

Cipher Pharmaceuticals announces fourth-quarter and fiscal year 2009 results

Cipher Pharmaceuticals Inc. today announced its financial and operational results for the fourth quarter and fiscal year ended December 31, 2009.

17 Feb 2010

Eleven Biotherapeutics announces completion of $35M Series A funding

Eleven Biotherapeutics, a biopharmaceutical company focused on translating breakthrough discoveries from science and medicine to engineer and develop innovative protein-based therapeutics, announced today it has completed a $35 million Series A financing co-led by Flagship Ventures and Third Rock Ventures. Proceeds from the financing will be used to build the research and development and business development teams for Eleven Biotherapeutics, in addition to advancing the company’s portfolio of engineered proteins through clinical proof of concept.

17 Feb 2010

AHF to protest Merck’s Isentress pricing and policies at CROI

AIDS Healthcare Foundation (AHF) will host a protest Wednesday morning, February 17 at 8:00am targeting Merck and Co. Pharmaceuticals over the pricing and policies for its key HIV/AIDS drug, Isentress, the most expensive first-line AIDS treatment in the US, during the 17th Conference of Retroviruses and Opportunistic Infections (CROI) in San Francisco.

17 Feb 2010

Scotland's $13 billion chemicals sector to showcase new initiatives at Informex

Scotland's $13 billion chemicals sector will showcase innovative new initiatives at Informex this week, highlighting the country's research and manufacturing expertise, and offering integrated, world-class solutions to the global chemicals industry.

17 Feb 2010

Protein crucial in mediating anti-inflammatory actions of nuclear lipid receptors discovered

Researchers at the Swedish medical university Karolinska Institutet have discovered a protein that is crucial in mediating the anti-inflammatory actions of nuclear lipid receptors. The findings, published in the research journal Genes & Development, link lipid metabolism and inflammation and open up new possibilities for developing treatments of metabolic diseases associated with inflammation, such as diabetes and atherosclerosis.

17 Feb 2010

Waters launches new Viridis family of analytical and preparative SFC columns for compound purification

Waters Corporation introduces today Viridis™ SFC columns, a new family of analytical and preparative supercritical fluid chromatography (SFC) columns. Waters new Viridis SFC columns were developed to give laboratories using SFC a reliable source of high-quality columns for compound purification. Paired with Waters® TharSFC™ instrumentation laboratories now have a single source for both instrumentation and columns for their all-important purification work.

17 Feb 2010

Orexo AB reports year-end 2009 financial results

Sales of Abstral continue to show robust growth, with royalty revenues rising sharply during the fourth quarter – up threefold from the preceding quarter. Our partner, ProStrakan, launched during 2009 Abstral in UK, Germany, France, Spain and Greece, and product launches in additional markets are imminent. Sales growth confirms that there is a substantial medical requirement in the case of cancer patients suffering from breakthrough pain.

17 Feb 2010

Obecure enters into licensing and clinical supply agreement with Grunenthal's subsidiary for XR betahistine

Obecure Ltd (http://www.obecure.com)., a subsidiary of Bio-Light Israeli Life Science Investments Ltd., announced today the execution of a licensing and clinical supply agreement with Farmaceutici Formenti SPA, the Italian Subsidiary of the Grunenthal Group.

17 Feb 2010

Pharmaceuticals News and Research

Pharmaceutical Institute launches Employers and Retail Pharmacy e-courses

Quintiles launches QTEA solution to speed patient recruitment

Roche Molecular Systems, Merck Sharp & Dohme announce cancer therapeutics collaboration

Javelin Pharmaceuticals’ Dyloject NDA receives FDA PDUFA date

Genzyme announces fourth-quarter and full-year 2009 financial results

Codexis announces two separate collaborations in pharmaceutical manufacturing

Athersys completes enrollment in phase I MultiStem allogeneic stem cell therapy clinical trial

Tioga Pharmaceuticals to utilize $18M equity funding for Phase 3 clinical trial of asimadoline

Pharmatek Laboratories meets DEA requirements for developing and manufacturing controlled substances

Dyax announces fourth-quarter and full-year 2009 financial results

FDA approved cannabis medicines needed for veterans to relieve symptoms of PTSD

Derma Sciences announces pricing of public offering of 972,000 shares of its common stock

Cipher Pharmaceuticals announces fourth-quarter and fiscal year 2009 results

Eleven Biotherapeutics announces completion of $35M Series A funding

AHF to protest Merck’s Isentress pricing and policies at CROI

Scotland's $13 billion chemicals sector to showcase new initiatives at Informex

Protein crucial in mediating anti-inflammatory actions of nuclear lipid receptors discovered

Waters launches new Viridis family of analytical and preparative SFC columns for compound purification

Orexo AB reports year-end 2009 financial results

Obecure enters into licensing and clinical supply agreement with Grunenthal's subsidiary for XR betahistine

Free eBook - From lab to market: Accelerate your bioprocessing journey eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Managing vibration in IVF laboratories

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence